J.Jill, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by J.Jill, Inc. on March 24, 2020. The filing addresses a regulatory notice received from the New York Stock Exchange (NYSE) regarding the Company's compliance with continued listing standards. The Company's common stock trades under the symbol "JILL" on the NYSE.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on listing status and regulatory compliance.
Material Changes
- Listing Status: The Company received notice from the NYSE that it failed to maintain the required average closing share price of at least $1.00 over a consecutive 30-trading-day period (Section 802.01C of the Listed Company Manual).
- Trading Symbol: The Company's stock will trade under the symbol "JILL.BC" to indicate "below compliance" status.
- Cure Period: The Company has six months from the date of the notice to regain compliance.
Outlook, Risks, and Management Commentary
Compliance Requirements: To regain compliance, the Company must achieve a closing price of at least $1.00 per share and an average closing price of at least $1.00 per share over a 30-trading-day period ending on the last trading day of any calendar month during the cure period. Failure to do so may result in suspension and delisting.
Operational Impact: Management states the notice has no immediate impact on business operations, SEC reporting obligations, or material debt agreements. It does not constitute an event of default.
Risks: The filing highlights risks related to the potential suspension of trading, the ability to develop and execute a plan to regain compliance, and the impact of the COVID-19 epidemic on the economy and consumer demand.
Investor Verification Checklist
- Verify the current trading symbol and status of J.Jill stock on the NYSE (JILL.BC).
- Monitor the Company's stock price performance over the next six months to assess compliance progress.
- Review the press release dated March 30, 2020 (Exhibit 99.1) for any specific plans to address the share price deficiency.
- Check subsequent filings for updates on the cure period status or potential delisting proceedings.